Home page | Servier US
Servier is a leader in oncology and is building up its neurology business. We are dedicated to addressing rare diseases and patient populations with unmet needs.
Servier is a pharma company governed by a non-profit foundation
Welcome to the Servier website. Use the search field to explore our articles and resources. News 21.11.2025
Servier US Medical Affairs
Resources created by Servier healthcare professionals, for US healthcare professionals.
MyServier | Servier's resources hub for healthcare professionals
MyServier is Servier’s resources hub for healthcare professionals, offering access to scientific resources, tools, and specialized content. Available across multiple countries, it supports …
About Our Leadership in Oncology | Servier US
At Servier, we bring the patient voice into everything we do, and our commitment to patients extends far beyond approval. At Servier, each person is propelled by a collective mission to …
Newsroom | Servier - News Releases
Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The …
At Servier, we draw strength from our independence
As a global pharmaceutical Group, we help to drive considerable therapeutic progress. Pursuing our vocation, we bolster our presence in regions where patient needs are greatest. Since …
Our group - Servier ME – a global pharmaceutical group …
Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a …
Cellectis Announces Arbitral Decision in Dispute with Servier
5 days ago · NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using …
FDA approves vorasidenib for Grade 2 astrocytoma or …
On August 6, 2024, the Food and Drug Administration approved vorasidenib (Voranigo, Servier Pharmaceuticals LLC), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 …